MedCity News October 1, 2024
Kailera Therapeutics licensed its portfolio of metabolic disorder drugs from Hengrui. The most advanced program has results from a Phase 2 test in China suggesting it could be competitive with other medications that target the GLP-1 and GIP receptors to trigger weight loss.
Eli Lilly showed a drug that goes after two metabolic targets to treat obesity can successfully shed weight and become a revenue-generating heavyweight. Other companies aspire to improve on the Lilly drug’s approach and Kailera Therapeutics is the newest of them, backed by $400 million to support a pipeline of obesity drug candidates.
Kailera, which splits its operations between San Diego and Waltham, Massachusetts, is joining a growing field of companies developing drugs that mimic peptides in...
Today's Sponsors
Today's Sponsor